Cannabis Abuse and the Course of Recent-Onset Schizophrenic Disorders

Archives of General Psychiatry

Volumn 51, Issue 4, 1994, Pages 273-279

  Linszen, Don H ^a   Dingemans, Peter M ^a   Lenior, Marie E ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS;

ADOLESCENT; ADULT; ARTICLE; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RECURRENCE RISK; RELAPSE; RISK ASSESSMENT; SCHIZOPHRENIA; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; AMBULATORY CARE; COHORT STUDIES; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMAN; MALE; MARIJUANA ABUSE; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUPPORT, NON-U.S. GOV'T;

EID: 0028316414     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1994.03950040017002     Document Type: Article

References (27)

1. Weil AT. Adverse reactions to marijuana, classification and suggested treatment. N Engl J Med. 1970;282: 997–1000.
2. Chopra GS, Smith JW. Psychotic reactions following cannabis use in East Indians. Arch Gen Psychiatry. 1974;30: 24–27.
3. Treffert DA. Marijuana use in schizophrenia: a clear hazard. Am J Psychiatry. 1978;135: 1213–1215.
4. Negrete JC, Knapp WP, Douglas DE, Smith B. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol Med. 1986;16: 515–520.
5. Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown GM, Franco S. Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function. J Clin Psychiatry. 1991;52: 26–30.
6. Knudsen P, Vilmar T. Cannabis and neuroleptic agents in schizophrenia. Acta Psychiatr Scand. 1984;69: 162–174.
7. Rottanburgh D, Robins AH, Ben-Arie O, Teggin A, Elk R. Cannabis-associated psychosis with hypomanic features. Lancet. 1982;2: 1364–1366.
8. Peralta V, Cuesta MJ. Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand. 1992;85: 127–130.
9. American Psychiatric Association, Committee on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
10. Nuechterlein KH, Snyder KS, Dawson ME, Rappe S, Gitlin M, Fogelson D. Expressed emotion, fixed dose fluphenazine decanoate maintenance and relapse in recent-onset schizophrenia. Psychopharmacol Bull. 1986;22: 663–639.
11. Kokes R, Strauss J, Klorman R. Measuring premorbid adjustment: the instruments and their development. Schizophr Bull. 1977;3: 186–213.
12. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10: 799–812.
13. Linszen DH, Dingemans PMAJ, Scholte WF, et al. Behandeling, ‘expressed emotion’ en recent ontstane schizofrenie en verwante stoornissen. Tijdschr Psychiatr. 1993;9: 625–640.
14. Thiemann S, Csernansky JG, Berger PA. Rating scales in research: the case of negative symptoms. Psychiatry Res. 1987;20: 47–55.
15. Czobor P, Bitter I, Volavka J. Relationship between Brief Psychiatric Rating Scale for the assessment of negative symptoms: a study of their correlation and redundancy. Psychiatry Res. 1991;36: 129–139.
16. Norusis MJ. SPSSPC+ 4.0 Base Manual for the IBM PC/XT/AT and PS/2. Chicago, Ill: SPSS Inc; 1990.
17. Dixon MJ, Brown MB, Engelman L, et al, eds. BMDP Statistical Software Manual. Berkeley: University of California Press; 1990;1–2.
18. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health Longitudinal Study of Chronic Schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry. 1991;48: 239–246.
19. Hollingshead AB, Redlich FC. Social Class and Mental Illness. New York, NY: John Wiley & Sons Inc; 1968: 387–397.
20. Strauss JS, Carpenter WT. Prediction of outcome in schizophrenia, III: Five-year outcome and its predictors. Arch Gen Psychiatr. 1977;34: 159–163.
21. Martin GW, Wilkinson A, Kapur BM. Validation of self-reported cannabis use by urine analysis. Addict Behav. 1988;13: 147–150.
22. Andreasson S, Allebeck P, Engström A, Rydberg U. Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet. 1987;2: 1483–1486.
23. Gardner EL, Lowinson JH. Marijuana's interaction with brain reward systems: update 1991. Pharmacol Biochem Behav. 1991:40: 571–580.
24. McKena PJ. Pathology, phenomenology and the dopamine hypothesis of schizophrenia. Br J Psychiatry. 1987;151: 288–301.
25. Schneier FR, Siris SG. A review of psychoactive substance use and abuse in schizophrenia: patterns of drug choice. J Nerv Ment Dis. 1987;175: 641–652.
26. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry. 1991;148: 224–230.
27. Thornicroft G. Cannabis and psychosis: is there epidemiological evidence for an association? Br J Psychiatry. 1990;157: 25–33.